Understand the source comparison
Peptides for Belly Fat: Evidence Comparison
GH Secretagogues (CJC-1295/Ipamorelin) Stimulates endogenous GH release, increases lipolysis via hormone-sensitive lipase activation 6–9% reduction in visceral adipose tissue over 12 weeks (JCEM study) Subcutaneous injection, 5 days/week Most direct mechanism
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GH Secretagogues (CJC-1295/Ipamorelin)
- Stimulates endogenous GH release, increases lipolysis via hormone-sensitive lipase activation
- 6–9% reduction in visceral adipose tissue over 12 weeks (JCEM study)
- Subcutaneous injection, 5 days/week
- Most direct mechanism for visceral fat mobilization through elevated GH pulse amplitude
- GLP-1 Receptor Agonists (Mazdutide, Survodutide)
- Reduces appetite, improves insulin sensitivity, slows gastric emptying
- 12–16% total body weight reduction with disproportionate visceral fat loss
- Subcutaneous injection, weekly dosing
- Best for metabolic fat loss when insulin resistance drives visceral accumulation
- Ghrelin Mimetics (MK-677)
- Oral ghrelin receptor agonist, increases GH and IGF-1 without injection
- 40–90% IGF-1 elevation correlates with reduced waist-to-hip ratio
- Oral capsule, once daily
- Convenient alternative to injectable GH secretagogues with sustained 24-hour effect
- Triple Reuptake Inhibitors (Tesofensine)
- Increases norepinephrine, dopamine, serotonin; activates beta-adrenergic lipolysis
- 10.6% body weight reduction at 24 weeks (Phase 2 trial)
- Thermogenic mechanism preferentially targets visceral fat through beta-receptor activation